Ignite Creation Date:
2025-12-24 @ 3:30 PM
Ignite Modification Date:
2026-01-05 @ 6:33 PM
Study NCT ID:
NCT05496192
Status:
WITHDRAWN
Last Update Posted:
2023-04-14
First Post:
2022-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-06-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-24
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-09
First Submit QC Date:
None
Study First Post Date:
2022-08-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-12
Last Update Post Date:
2023-04-14
Last Update Post Date Type:
ACTUAL